Drug Patents owned by Acrotech

1. List of Beleodaq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6888027 ACROTECH Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH Pharmaceutical formulations of HDAC inhibitors
Oct, 2027

(4 years from now)

Drugs and Companies using BELINOSTAT ingredient

Market Authorisation Date: 03 July, 2014

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of BELEODAQ before it's patent expiration?
More Information on Dosage

2. List of Evomela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 ACROTECH Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9200088 ACROTECH Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US10864183 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(7 years from now)

US11020363 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(7 years from now)

US10940128 ACROTECH Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
Jun, 2030

(7 years from now)

US9493582 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(10 years from now)

US10040872 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same
Jan, 2034

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's patent expiration?
More Information on Dosage

3. List of Folotyn drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6028071 ACROTECH Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Jul, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7622470 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(2 years from now)

US8299078 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(2 years from now)

Drugs and Companies using PRALATREXATE ingredient

Market Authorisation Date: 24 September, 2009

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of FOLOTYN before it's patent expiration?
More Information on Dosage

4. List of Fusilev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6500829 ACROTECH Substantially pure diastereoisomers of tetrahydrofolate derivatives
Mar, 2022

(11 months ago)

Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient

Market Authorisation Date: 07 March, 2008

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of FUSILEV before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in